

## SUPPLEMENTARY MATERIAL

**Table S1:** Basic demographic and clinical characteristics of different patients (first episode only)

	Overall (n = 233)	Fluconazole (n = 83)	Posaconazole (n = 150)	p-value
Age, mean ± SD	49.7 ± 13.6	47.7 ± 14.1	50.8 ± 13.2	0.097
Age > 50 years, n (%)	128 (54.9)	39 (47.0)	89 (59.3)	0.075
Female, n (%)	102 (43.8)	36 (43.4)	66 (44.0)	1.000
AML/MDS, n (%)	203 (87.1)	66 (79.5)	137 (91.3)	<b>0.014</b>
First induction, n (%)	203 (87.1)	80 (96.4)	123 (82.0)	<b>0.002</b>
Previous HSCT, n (%)	22 (9.4)	4 (4.8)	18 (12.0)	0.100
Neutropenia <500* (days), mean ± SD	18.7 ± 8.6	19.0 ± 10.1	18.6 ± 7.7	0.738
Neutropenia <100* (days), mean ± SD	10.1 ± 5.6	8.6 ± 5.3	10.9 ± 5.6	<b>0.003</b>
Follow-up (days), mean ± SD	47.5 ± 26.1	48.0 ± 26.8	47.3 ± 25.7	0.848

Statistically significant values (<0.05) are shown in bold

\* Absolute neutrophil count (cells/μL)

SD = Standard deviation; AML = Acute myelogenous leukemia; MDS = Myelodysplastic syndrome

**Table S2:** IFI incidence among first episodes (n = 233), according to galactomannan criteria

Galactomannan criteria	Proven/probable IFI cases			p-value*
	Total	Fluconazole Group, n = 83 (%)	Posaconazole Group, n = 150 (%)	
Galactomannan ≥ 0.5	17	12 (16.9)	5 (3.4)	0.003
Galactomannan 2020 criteria	15	11 (13.3)	4 (2.7)	0.004

\* Fisher's exact test

IFI = Invasive fungal infection